PharmaShots Weekly Snapshots (January 30 - February 03, 2023)
Date: Feb 03, 2023 | Tags: 4D Molecular Therapeutics, 4D-150, Diabetic Macular Edema, Regulatory, US, FDA, IND
Date: Feb 03, 2023 | Tags: AstraZeneca, Amgen, Tezspire, Tezepelumab, Severe Asthma, Regulatory, US, FDA, Approval
Date: Feb 03, 2023 | Tags: Abbott, TactiFlex Sensor Enabled Ablation Catheter, FlexAbility SE Ablation Catheter, Abnormal Heart Rhythms, Regulatory, US, FDA, EU
Date: Feb 03, 2023| Tags: Shanghai Henlius Biotech, HLX15, biosimilar, daratumumab, Multiple Myeloma, Clinical Trial, P-I Trial
Date: Feb 03, 2023 | Tags: Amylyx, AMX0035, Amyotrophic Lateral Sclerosis, Clinical Trial, P-III, PHOENIX Trial
Date: Feb 03, 2023 | Tags: Guardant Health, AnHeart Therapeutics, Taletrectinib, Guardant360 CDx, Guardant360 TissueNext
Date: Feb 02, 2023 | Tags: Karuna Therapeutics, Goldfinch Bio, TRPC4/5, GFB-887, psychiatric, neurological conditions, mood, anxiety disorders, Pharma
Date: Feb 02, 2023 | Tags: Tonix, University of Maryland, TNX-1500, Rejection, Heart Xenograft Transplantation, Animals Health
Date: Feb 02, 2023 | Tags: Aulos Bioscience, AU-007, Solid Tumors, Clinical Trial, P-I/II
Date: Feb 02, 2023 | Tags: Orbit Discovery, Endevica Bio, Cachexia, Pharma
Date: Feb 02, 2023 | Tags: Miromatrix, Baxter, Bioengineered Liver Replacement Therapy, miroliverELAP, Acute Liver Failure, PrisMax system, Biotech
GSK’s Jesduvroq (daprodustat) Receives the US FDA’s Approval for the Treatment of Anaemia
Date: Feb 02, 2023 | Tags: GSK, Jesduvroq, daprodustat, Anaemia, chronic kidney disease, Regulatory, US, FDA, Approval
Date: Feb 01, 2023 | Tags: Roche, Hemlibra, emicizumab, Moderate Haemophilia, Label Expansion, Approval, EC, Regulatory
Biosynex Entered into a Definitive Merger Agreement to Acquire Chembio Diagnostics for ~$17.2M
Date: Feb 01, 2023 | Tags: Biosynex, Chembio Diagnostics, infectious diseases, ~$17.2M, M&A
Date: Feb 01, 2023 | Tags: Jazz Pharmaceuticals, Epidyolex, cannabidiol, Seizures, tuberous sclerosis complex, NICE, England, Regulatory
Amgen Launches First Humira (adalimumab) Biosimilar Amjevita in the US
Date: Feb 01, 2023 | Tags: Amgen, Humira, adalimumab, biosimilar, Amjevita, US
Date: Feb 01, 2023 | Tags: Context Therapeutics, Stemline Therapeutics, Orserdu, elacestrant, Breast Cancer, Regulatory, US, FDA, Approval
Date: Feb 01, 2023 | Tags: uniQure, Apic Bio, APB-102, Amyotrophic Lateral Sclerosis, SOD1 Mutations, Pharma
Date: Jan 31, 2023 | Tags: Sciwind Biosciences, Ecnoglutide, XW003, Type 2 Diabetes, China, Clinical Trial, P-III Trials
Idorsia Reports MAA Submission of Aprocitentan to EMA for the Treatment of Resistant Hypertension
Date: Jan 31, 2023 | Tags: Idorsia, Aprocitentan, Resistant Hypertension, MAA, EMA, Regulatory
Date: Jan 31, 2023 | Tags: Alpha Biopharma, Zorifertinib, EGFR-Mutated NSCLC, CNS, Metastases, Regulatory, NMPA Acceptance, NDA
Sandoz Receives EMA’s CHMP Positive Opinion of Adalimumab Biosimilar
Date: Jan 31, 2023 | Tags: Sandoz, Hyrimoz, Adalimumab, Biosimilar, rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis, Regulatory, EMA, CHMP
Date: Jan 31, 2023 | Tags: Daiichi Sankyo, Datopotamab Deruxtecan, Non-Small Cell Lung Cancer, Clinical Trial, P-III, TROPION-Lung07 Trial
Date: Jan 31, 2023 | Tags: Guardant Health, Guardant360 CDx Liquid Biopsy Test, Breast Cancer, Regulatory, US, FDA, Approval, MedTech
Date: Jan 30, 2023 | Tags: Janssen, Carvykti, cilta-cel, Multiple Myeloma, P-III, CARTITUDE-4 Study, Clinical Trial
Date: Jan 30, 2023 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, Eosinophilic Esophagitis, Regulatory, EC, Approval
Date: Jan 30, 2023 | Tags: Abbott, Proclaim XR Spinal Cord Stimulation System, Painful Diabetic Peripheral Neuropathy, Regulatory, US, FDA, Approval, MedTech
Date: Jan 30, 2023 | Tags: Merck, Keytruda, pembrolizumab, Non-Small Cell Lung Cancer, Regulatory, US, FDA, Approval
Date: Jan 30, 2023 | Tags: BMS, Reblozyl, luspatercept, Anemia-Associated, Non-Transfusion-Dependent Beta Thalassemia, Regulatory, EMA, CHMP
Date: Jan 30, 2023 | Tags: Eli Lilly, Jaypirca, pirtobrutinib, Mantle Cell Lymphoma, US, FDA, Approval
Related Post: PharmaShots Weekly Snapshots (January 23 - 27, 2023)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.